Author:
Kemmeren Jeanet M.,van der Maas Nicoline AT,de Melker Hester E.
Publisher
Springer Science and Business Media LLC
Subject
Pediatrics, Perinatology and Child Health
Reference30 articles.
1. Omer SB, Salmon DA, Orenstein WA, deHart MP, Halsey N (2009) Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases. N Engl J Med 360:1981–1988
2. Chen RT, Glasser JW, Rhodes PH, Davis RL, Barlow WE, Thompson RS, Mullooly JP, Black SB, Shinefield HR, Vadheim CM, Marcy SM, Ward JI, Wise RP, Wassilak SG, Hadler SC (1997) Vaccine safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team Pediatrics 99:765–773
3. Tozzi AE, Asturias EJ, Balakrishnan MR, Halsey NA, Law B, Zuber PL (2013) Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use. Vaccine 31:5041–5046
4. Aristegui J, Dal-Re R, Diez-Delgado J, Mares J, Casanovas JM, Garcia-Corbeira P, De Frutos E, Van Esso D, Verdaguer J, De la Flor J, Moraga F, Boceta R, Garcia-Martinez JA (2003) Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Vaccine 21:3593–3600
5. van den Bergh MR, Spijkerman J, Francois N, Swinnen K, Borys D, Schuerman L, Veenhoven RH, Sanders EA (2016) Immunogenicity, safety and reactogenicity of a booster dose of the 10-valent pneumococcal nontypeable H. influenzae protein D conjugate vaccine coadministered with DTPa-IPV-Hib in Dutch children: a randomized controlled trial. Pediatr Infect Dis J 35:e206–e219